Name: UMIN ID:
Unique ID issued by UMIN | UMIN000018722 |
---|---|
Receipt number | R000021098 |
Scientific Title | Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with tri-weekly docetaxel (D) followed by doxorubicin, 5-fluorouracil, and cyclophosphamide (FEC) or docetaxel with concurrent use of capecitabine (TX) followed by doxorubicin, cyclophosphamide, and capecitabine (CEX) in women with locally advanced triple-negative breast cancer |
Date of disclosure of the study information | 2015/10/01 |
Last modified on | 2017/08/29 11:41:49 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2015/08/19 12:56:38 | ||
2 | Update | 2015/08/20 10:44:25 | Target sample size |
|
3 | Update | 2017/08/29 11:41:49 | Name of primary person or sponsor Organization |